Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:59AM ET
1.20
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-2.45 Insider Own22.02% Shs Outstand10.56M Perf Week13.21%
Market Cap12.67M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.23M Perf Month-1.23%
Income-10.52M PEG- EPS next Q- Inst Own1.05% Short Float1.29% Perf Quarter0.00%
Sales0.15M P/S84.48 EPS this Y- Inst Trans-81.20% Short Ratio0.05 Perf Half Y20.00%
Book/sh1.11 P/B1.08 EPS next Y- ROA-80.41% Short Interest0.11M Perf Year-80.00%
Cash/sh0.08 P/C15.84 EPS next 5Y- ROE-158.22% 52W Range0.67 - 9.60 Perf YTD3.45%
Dividend Est.- P/FCF- EPS past 5Y12.78% ROI-113.72% 52W High-87.50% Beta0.74
Dividend TTM- Quick Ratio0.28 Sales past 5Y2003.75% Gross Margin-112.28% 52W Low78.07% ATR (14)0.09
Dividend Ex-Date- Current Ratio0.28 EPS Y/Y TTM53.37% Oper. Margin-5390.35% RSI (14)50.28 Volatility9.76% 5.83%
Employees19 Debt/Eq0.28 Sales Y/Y TTM-84.28% Profit Margin-6898.68% Recom3.00 Target Price20.20
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q73.75% Payout- Rel Volume0.28 Prev Close1.20
Sales Surprise- EPS Surprise- Sales Q/Q-99.63% EarningsNov 15 BMO Avg Volume2.24M Price1.20
SMA201.39% SMA50-4.70% SMA200-37.47% Trades Volume258,757 Change0.00%
Mar-26-24 08:30AM
Mar-21-24 08:30AM
Mar-19-24 08:30AM
Mar-14-24 09:30AM
Feb-27-24 08:30AM
08:30AM Loading…
Feb-15-24 08:30AM
Feb-12-24 08:30AM
Feb-08-24 09:17AM
Jan-03-24 07:24AM
Dec-07-23 08:30AM
Dec-05-23 08:30AM
Nov-21-23 08:30AM
Nov-16-23 10:05AM
Nov-15-23 09:00AM
Oct-26-23 08:30AM
08:30AM Loading…
Oct-17-23 08:30AM
Oct-09-23 08:30AM
Aug-23-23 08:30AM
Aug-17-23 09:19AM
Aug-10-23 08:30AM
Aug-07-23 08:30AM
Aug-03-23 09:20AM
Aug-01-23 08:30AM
Jul-31-23 09:30AM
Jul-27-23 09:22AM
Jul-26-23 08:30AM
Jul-24-23 12:30PM
Jul-06-23 08:30AM
Jun-26-23 08:30AM
Jun-20-23 08:30AM
08:30AM Loading…
Jun-12-23 08:30AM
Jun-06-23 08:30AM
May-22-23 08:30AM
May-04-23 08:30AM
Apr-26-23 08:30AM
Apr-10-23 08:30AM
Apr-06-23 08:30AM
Mar-31-23 06:49PM
Mar-20-23 07:00AM
Mar-14-23 07:00AM
Feb-28-23 08:30AM
Feb-23-23 04:16PM
Feb-21-23 08:30AM
Jan-19-23 08:30AM
Jan-18-23 08:25AM
Jan-05-23 08:30AM
Dec-20-22 11:05AM
Nov-17-22 08:30AM
05:16AM
Nov-14-22 06:20PM
Nov-07-22 08:30AM
Nov-02-22 08:30AM
Oct-05-22 08:30AM
Sep-23-22 08:30AM
Sep-16-22 09:36AM
Sep-13-22 08:30AM
Sep-09-22 08:30AM
Aug-22-22 08:30AM
Aug-18-22 08:30AM
Aug-15-22 05:48PM
Aug-02-22 08:30AM
Jul-18-22 08:30AM
Jul-13-22 08:30AM
Jul-06-22 08:30AM
Jun-30-22 08:30AM
Jun-21-22 08:30AM
Jun-16-22 08:30AM
Jun-10-22 08:30AM
Jun-07-22 01:10PM
Jun-01-22 08:30AM
May-25-22 08:30AM
May-23-22 07:30AM
May-16-22 05:46PM
03:25PM
May-13-22 08:30AM
May-12-22 09:00AM
08:30AM
May-10-22 08:30AM
May-05-22 08:30AM
May-03-22 08:30AM
Apr-28-22 08:30AM
Apr-26-22 08:30AM
Mar-31-22 04:18PM
Mar-23-22 09:25AM
Mar-08-22 06:15AM
Feb-02-22 08:00AM
Jan-05-22 08:30AM
Dec-22-21 08:30AM
Dec-15-21 08:30AM
Dec-10-21 01:38PM
05:17AM
Dec-09-21 08:30AM
Nov-15-21 04:33PM
Nov-11-21 09:00AM
Nov-03-21 11:18AM
Nov-02-21 06:18AM
Nov-01-21 11:32AM
10:51AM
10:21AM
07:28AM
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.